Are we missing tracks while prescribing proton pump inhibitors? - An opinion from clinicians cross sectional hospital based questionnaire study

Abstract

Introduction: Poton pump inhibitors are the main stage standard therapy for various gastrointestinal disorders such as upper gastrointestinal disorders, GERD, dyspepsia and peptic ulcer disease.1 The availability of PPIs as an OTC drug and it's over utilization in multiple disease backgrounds with or without symptoms has subjected patients to a potential risk such as parietal cell hypertrophy and hypergastrinemia leading to rebound acid secretion.2 Studies have shown that between 40% to 65% of prescriptions for a PPI fail to have an appropriate indication.3 Inapt stress ulcer prophylaxis (SUP) in hospital wards and in the clinical OPDs, and failure to discontinue SUP prior to hospital discharge has amplified this risk.